Tag Archive for: Staphylococcus

Destiny Pharma Lancet Report

/in

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more

Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

/in

Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potential of XF-73 nasal product as alternative to mupirocin Brighton, United Kingdom – 18 October 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life […]

Read more